Triple Negative Breast Cancer technology
Theratechnologies
A novel and targeted treatment platform in oncology being developed based on new proprietary peptides targeting sortilin receptors. The overexpression of sortilin receptors has been documented in numerous human cancers including ovarian and breast cancers. Targeting sortilin receptors could therefore lead to a selective delivery approach as well as a specific internalization of a number of anticancer agents that can be linked to these peptides.
For more information, visit: www.TheraTech.com
3D animations are great support to explain the mechanism of action of a molecule. With the help of Amerra, we were able to convey how our promising peptide-drug conjugate technology works inside the body. Amerra produced such an amazing result at a cost a small biotech like us can afford. We’re very much looking forward to working with them on our next animated video.
